I would say they would be going for a regional Asia deal. The current trial is narmafotinib + gemcitabine/abraxane which is the chemotherapy regime traditionally used over here and Asia for pancreatic ca.
In the USA they use FOLFIRINOX, which we are planning to do a separate phase 2 trial with in 2025, hence I think any US deal/takeover would be post the FOLFIRINOX study if successful.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.001(1.00%) |
Mkt cap ! $35.46M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.6¢ | $182.1K | 1.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 141572 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5555251 | 7 |
View Market Depth
| Last trade - 15.35pm 14/11/2024 (20 minute delay) ? |
| ATX (ASX) Chart |